SurModics, Inc.  

(Public, NASDAQ:SRDX)   Watch this stock  
Find more results for SRDX
25.45
+0.25 (0.99%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.95 - 25.70
52 week 21.90 - 30.75
Open 25.15
Vol / Avg. 71,499.00/39,094.00
Mkt cap 341.24M
P/E 35.88
Div/yield     -
EPS 0.71
Shares 13.28M
Beta 1.04
Inst. own 87%
Jul 26, 2017
Q3 2017 Surmodics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 6, 2017
Surmodics Inc at Jefferies Healthcare Conference
May 24, 2017
Surmodics Inc at B. Riley Investor Conference
Apr 27, 2017
Q2 2017 Surmodics Inc Earnings Release
Apr 27, 2017
Q2 2017 Surmodics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 2.89% 13.99%
Operating margin 9.58% 23.62%
EBITD margin - 34.71%
Return on average assets 1.56% 8.62%
Return on average equity 1.87% 10.05%
Employees 219 -
CDP Score - -

Address

9924 W 74th St
EDEN PRAIRIE, MN 55344-3523
United States - Map
+1-952-5007000 (Phone)
+1-952-5007001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Officers and directors

Susan E. Knight Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Gary R. Maharaj President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Andrew D. C. LaFrence Vice President of Finance and Information Systems and Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Thomas A. Greaney Executive Vice President of Medical Devices
Age: 50
Bio & Compensation  - Reuters
Bryan K. Phillips Senior Vice President - Legal and Human Resources, General Counsel & Secretary
Age: 45
Bio & Compensation  - Reuters
Charles W. Olson Senior Vice President of Commercial and Business Development, Medical Devices
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph J. Stich Vice President, General Manager - In Vitro Diagnostics
Age: 51
Bio & Compensation  - Reuters
Timothy J. Arens Vice President - Corporate Development and Strategy
Age: 49
Bio & Compensation  - Reuters
Gregg S. Sutton Vice President - Research & Development
Age: 57
Bio & Compensation  - Reuters
Lisa Wipperman Heine Director
Age: 53
Bio & Compensation  - Reuters